These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26874926)

  • 21. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
    Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws.
    Kagami H; Inoue M; Kobayashi A; Taguchi A; Li X; Yoshizawa M
    Oral Dis; 2018 Mar; 24(1-2):52-56. PubMed ID: 29480637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
    Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
    PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab.
    Niibe K; Ouchi T; Iwasaki R; Nakagawa T; Horie N
    J Prosthodont Res; 2015 Jan; 59(1):3-5. PubMed ID: 25212129
    [No Abstract]   [Full Text] [Related]  

  • 25. [Oral bisphosphonates, denosumab and osteonecrosis of the jaws].
    Cardona Tortajada F; Sainz Gómez E; Viñal Lozano D
    Aten Primaria; 2015 May; 47(5):319-20. PubMed ID: 25523928
    [No Abstract]   [Full Text] [Related]  

  • 26. Osteonecrosis of the jaw.
    Drozdzowska B
    Endokrynol Pol; 2011; 62(1):88-92. PubMed ID: 21365586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
    Higuchi T; Soga Y; Muro M; Kajizono M; Kitamura Y; Sendo T; Sasaki A
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jun; 125(6):547-551. PubMed ID: 29574058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. More about osteonecrosis.
    Finkelman RD; Clemons M; Bouganim N
    J Am Dent Assoc; 2011 Apr; 142(4):371-2; author reply 372-4. PubMed ID: 21454842
    [No Abstract]   [Full Text] [Related]  

  • 29. Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature.
    Chehal H; Nikitakis NG; Islam MN; Goodchild JH; Mordini L; Bhattacharyya I
    Gen Dent; 2019; 67(1):42-46. PubMed ID: 30644830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Jaw problems: Update on ARONJ.
    Kyriakidou E; Badr M; Harrison S; Atkins S
    Br Dent J; 2015 Jul; 218(12):662-3. PubMed ID: 26114687
    [No Abstract]   [Full Text] [Related]  

  • 31. Osteonecrosis of the jaw and the role of macrophages.
    Pazianas M
    J Natl Cancer Inst; 2011 Feb; 103(3):232-40. PubMed ID: 21189409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cause of osteonecrosis.
    Karatekin BD; Yasin S; Icagasioglu A; Karatekin AO; Ceyran AB
    Br Dent J; 2018 Apr; 224(8):559. PubMed ID: 29700459
    [No Abstract]   [Full Text] [Related]  

  • 33. [Bisphosphonate and denosumab-related osteonecrosis of the jaw: Epidemiology, diagnosis and management].
    Dupic G; Collangettes D; Dillies AF; Calvet L; Tournilhac O; Bay JO; Mahammedi H
    Bull Cancer; 2015 Dec; 102(12):1010-9. PubMed ID: 26607453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases.
    Yuan A; Munz A; Reinert S; Hoefert S
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Feb; 129(2):133-140. PubMed ID: 31606424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maxillar osteonecrosis associated to denosumab in a patient with systemic mastocytosis.
    Sánchez López JD; Cariati P; Pérez de Perceval Tara M
    Med Clin (Barc); 2018 Jul; 151(2):81-82. PubMed ID: 29162274
    [No Abstract]   [Full Text] [Related]  

  • 36. Aggressive denosumab-related jaw necrosis - a case series.
    Badr M; Kyriakidou E; Atkins S; Harrison S
    Br Dent J; 2017 Jul; 223(1):13-16. PubMed ID: 28684826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteonecrosis of the jaws.
    Toole J
    Rheumatology (Oxford); 2015 Oct; 54(10):1755-6. PubMed ID: 25877909
    [No Abstract]   [Full Text] [Related]  

  • 38. Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab.
    Yarom N; Lazarovici TS; Whitefield S; Weissman T; Wasserzug O; Yahalom R
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jan; 125(1):27-30. PubMed ID: 29102242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Denosumab and bisphosphonate associated bilateral osteonecrosis of the external auditory canal.
    True HD; Ricks RG; Smith JA
    Drug Ther Bull; 2023 Apr; 61(4):61-63. PubMed ID: 36008096
    [No Abstract]   [Full Text] [Related]  

  • 40. Antimicrobial peptide gene expression in medication-related osteonecrosis of the jaw.
    Thiel Y; Ghayor C; Lindhorst D; Essig H; Weber F; Rücker M; Schumann P
    Pathol Res Pract; 2020 Dec; 216(12):153245. PubMed ID: 33065485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.